Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Inclusion Criteria:

• Treated on the parent pembrolizumab studies established by the Sponsor asMK-3475-587 ready.

• Currently receiving pembrolizumab, pembrolizumab based combinations or lenvatinibfrom parent studies or in a follow-up phase.

Additional eligibility criteria for participants who enter Second Course Phase once they are enrolled on MK-3475-587:

• Has not received any anticancer systemic treatment since the last dose ofpembrolizumab or a pembrolizumab-based combination in First Course Phase.

• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Demonstrates adequate organ function.

• Have resolution of any toxic effect(s) of First Course Phase trial treatment withpembrolizumab or a pembrolizumab-based combination to Grade 1 or less (exceptalopecia) before trial treatment in Second Course Phase is started. If participantreceived major surgery or radiation therapy of >30 Gray (Gy), they must haverecovered from the toxicity and/or complications of the intervention.

• A female participant is eligible to enroll if she is not pregnant, notbreastfeeding, and ≥1 of the following conditions applies: A woman of childbearingpotential (WOCBP) who agrees to use contraception during the study treatment periodand for ≥120 days (corresponding to time needed to eliminate any study combinationtreatment(s) plus 30 days (a menstruation cycle) for study treatments with risk ofgenotoxicity.

Additional eligibility criteria for participants who enter dosing with Lenvatinib:

• Adequately controlled blood pressure (BP) to <150/90 mmHg, with or withoutantihypertensive medications.

• For male agrees to be abstinent from penile-vaginal intercourse OR agrees to use ahighly effective contraceptive method while receiving study drug and for 7 daysafter the last dose of lenvatinib.

• Is female and not pregnant/breastfeeding and at least one of the following appliesduring the study and for ≥4 days after: is not a woman of childbearing potential (WOCBP), is a WOCBP and uses highly effective contraception (low user dependencymethod OR a user dependent hormonal method in combination with a barrier method) oris a WOCBP who is abstinent from heterosexual intercourse.

Exclusion Criteria:

-There are no exclusion criteria to participate in MK-3475-587.

Participants are excluded from entering Second Course trial treatment once they are enrolled on MK-3475-587 if any of the following criteria applies:

• Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of itsexcipients.

• Has received a live vaccine within 30 days prior to the first dose of Second CoursePhase trial treatment.

• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form ofimmunosuppressive therapy within 7 days prior to the Cycle 1 Day 1 of Second CoursePhase.

• Has a known additional malignancy that is progressing or requires active treatment.Exceptions include early stage cancers (carcinoma in situ or Stage 1) treated withcurative intent, melanoma (non-ulcerated, thin primary), basal cell carcinoma of theskin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situbreast cancer that has undergone potentially curative therapy.

• Has known active central nervous system metastases and/or carcinomatous meningitis.

• Has an active autoimmune disease that has required systemic treatment in the past 2years (i.e., use of disease modifying agents, corticosteroids or immunosuppressivedrugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroidreplacement therapy for adrenal or pituitary insufficiency) is not considered a formof systemic treatment and is allowed.

• Has a history of (non-infectious) pneumonitis that required steroids or has currentpneumonitis. Note: Participants that experienced pneumonitis during First Coursethat did not meet the criteria for permanent discontinuation are eligible.

• Non-small cell lung cancer (NSCLC) participants only: Has interstitial lung disease.

• Has an active infection requiring systemic therapy.

• Has a known history of human immunodeficiency virus (HIV) infection.

• Has a known history of or is positive for hepatitis B or hepatitis C. For parentstudies where inclusion of participants with hepatitis was permitted, MK-3475-587will follow the parent study eligibility criteria for hepatitis.

• Is pregnant or breastfeeding or expecting to conceive or father children within theprojected duration of the study, starting with the Second Course Phase eligibilityVisit through 120 days after the last dose of study treatment.

• Has severe cardiovascular disease, i.e., arrhythmias, requiring chronic treatment,congestive heart failure (New York Heart Association Class III or IV) or symptomaticischemic heart disease.

• Has hepatic decompensation (Child-Pugh score >6 [class B and C]).

• Has uncontrolled thyroid dysfunction.

• Has uncontrolled diabetes mellitus.

• Has had an allogeneic tissue/solid organ transplant.

• Has a known history of active tuberculosis (TB; Bacillus tuberculosis).

Additional exclusion criteria for participants who enter dosing with Lenvatinib:

• Has had major surgery within 3 weeks prior to first dose of study intervention(s).

• Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.

• Has urine protein ≥1 g/24 hours.

• Has LVEF below the institutional (or local laboratory) normal range, as determinedby multigated acquisition scan (MUGA) or echocardiogram (ECHO).

• Has radiographic evidence of encasement or invasion of a major blood vessel, or ofintratumoral cavitation.

• Prolongation of QT intervals corrected for heart rate using Fridericia's (cube root)correction (QTcF) interval to >480 ms.

• Has clinically significant cardiovascular disease within 12 months from first doseof study intervention, including New York Heart Association Class III or IVcongestive heart failure, unstable angina, myocardial infarction, cerebral vascularaccident, or cardiac arrhythmia associated with hemodynamic instability.

• Gastrointestinal malabsorption or any other condition that might affect theabsorption of lenvatinib.

• Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks priorto the first dose of study drug.

• Has a history of any contraindication or has a severe hypersensitivity to anycomponents of lenvatinib.